Catalyst Initiates Enrollment in Phase II Cocaine Addiction Trial
Posted on: Monday, 28 January 2008, 12:00 CST
Catalyst Pharmaceutical Partners has initiated enrollment of patients for its 180- patient, US Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction.
The Phase II trial is designed as a randomized, double-blind, placebo- controlled, intent-to-treat, multi-center study to evaluate the safety and efficacy of CPP-109 as a treatment for cocaine addiction. Under the study protocol, patients will be treated for a period of 12 weeks, with an additional 12 weeks of follow-up.
The primary objective of the study is to demonstrate that a larger proportion of CPP-109-treated subjects than placebo- treated subjects are cocaine-free during their last two weeks of treatment (weeks 11 and 12). Additionally, Catalyst will be measuring a number of secondary endpoints based on reductions of cocaine use and craving. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vigabatrin.
Patrick McEnany, CEO of Catalyst, said: "We expect to add more clinical trial sites to the 10 previously disclosed in order to complete the trial as soon as possible. We anticipate initial top-line results from this trial to be available by year-end."
Source: Datamonitor
Related Articles
- Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
- Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction
- The Center for Radiation Therapy of Beverly Hills is First in California to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology
- Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology
- Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology
- University of Alabama at Birmingham First in the U.S. To Treat Cancer Patients With RapidArc(TM) Radiotherapy
- Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
- Medtronic Commences Large-Scale Clinical Trial to Evaluate Effectiveness of CRT-D in Japanese Patients
- Kansas Hospitals May Get $70 Million More for Treating Medicaid Patients
- Landmark Trial Will Evaluate the Impact of Treating Anemia on Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds